ZS Comsultants already talking to Companies about Cost Cutting

At the same time, some experts question whether the temporary changes enacted during the pandemic will lead to longer-term shifts in how pharmaceutical companies conduct their clinical and commercial businesses.

“I don’t think things will go back to status quo after this,” Pratap Khedkar, a principal at the consulting firm ZS, said by email. “Some are beginning to think through shifts they must make ... more digital, more telehealth, lower rep access, virtual meetings. Or if COVID-19 becomes the new flu and keeps recurring in waves.”